We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+8.1%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$377M
AUM Growth
-$57.5M
(-13%)
Cap. Flow
-$56.5M
Cap. Flow
% of AUM
-14.97%
Top 10 Holdings %
Top 10 Hldgs %
44.25%
Holding
64
New
18
Increased
9
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$17.1M |
| 2 |
CELG
Celgene Corp
CELG
|
+$15.2M |
| 3 |
Akebia Therapeutics
AKBA
|
+$9.63M |
| 4 |
Heron Therapeutics
HRTX
|
+$8.36M |
| 5 |
Omeros
OMER
|
+$7.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$38.6M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$21.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$20.5M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$16.5M |
| 5 |
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
|
+$15.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $20.4M | 5.41% |
478,800
+28,800
| +6% | +$994K |
|
|
2
Omeros
OMER
$845M
| $19.5M | 5.18% |
1,123,000
+623,000
| +125% | +$7.86M |
|
|
QCOR
3
DELISTED
QUESTCOR PHARMA INC
QCOR
| $18.5M | 4.9% |
+200,000
| New | +$17.1M |
|
4
Karyopharm Therapeutics
KPTI
$155M
| $17.9M | 4.75% |
25,667
+7,000
| +37% | +$3.26M |
|
|
DYAX
5
DELISTED
DYAX CORPORATION
DYAX
| $17.3M | 4.58% |
1,800,000
-200,000
| -10% | -$1.52M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $17.2M | 4.55% |
+200,000
| New | +$15.2M |
|
7
BioCryst Pharmaceuticals
BCRX
$2.42B
| $14.9M | 3.95% |
1,168,000
| – | – |
|
8
Jazz Pharmaceuticals
JAZZ
$16.1B
| $14.7M | 3.9% |
100,000
| – | – |
|
9
Puma Biotechnology
PBYI
$398M
| $13.7M | 3.63% |
207,500
| – | – |
|
10
Arrowhead Research
ARWR
$12.1B
| $12.9M | 3.41% |
900,000
-100,000
| -10% | -$1.31M |
|
|
11
Akebia Therapeutics
AKBA
$338M
| $11.1M | 2.95% |
+400,000
| New | +$9.63M |
|
12
Galectin Therapeutics
GALT
$230M
| $11M | 2.93% |
800,000
+452,000
| +130% | +$5.63M |
|
|
TSRO
13
DELISTED
TESARO, Inc.
TSRO
| $9.33M | 2.47% |
300,000
| – | – |
|
|
14
Heron Therapeutics
HRTX
$93.4M
| $8.62M | 2.29% |
+700,000
| New | +$8.36M |
|
15
DexCom
DXCM
$29B
| $7.93M | 2.1% |
800,000
-400,000
| -33% | -$3.54M |
|
|
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $7.63M | 2.02% |
500,000
-100,000
| -17% | -$1.44M |
|
|
MNK
17
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $7.2M | 1.91% |
+90,000
| New | +$6.52M |
|
18
Talphera
TLPH
$68M
| $7.17M | 1.9% |
35,000
-2,500
| -7% | -$501K |
|
19
Novavax
NVAX
$1.21B
| $6.93M | 1.84% |
75,000
+25,000
| +50% | +$2.2M |
|
|
XLRN
20
DELISTED
Acceleron Pharma
XLRN
| $6.79M | 1.8% |
+200,000
| New | +$6.69M |
|
|
SRNE
21
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $6.75M | 1.79% |
1,000,000
+300,000
| +43% | +$2.26M |
|
|
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
| $6.58M | 1.74% |
300,000
| – | – |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $5.84M | 1.55% |
200,000
| – | – |
|
24
Merck
MRK
$322B
| $5.79M | 1.53% |
104,800
-104,800
| -50% | -$5.72M |
|
|
EGRX
25
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $5.73M | 1.52% |
400,000
| – | – |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Cormorant Asset Management held 64 positions worth $377M, down 13% from $435M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Cormorant Asset Management withdrew a net $56.5M in Q2 2014, closing 10 positions and reducing 13 holdings. Its most notable exit was MEDIVATION, INC., an estimated $38.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 70% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in QUESTCOR PHARMA INC worth $18.5M.
- Cormorant Asset Management's largest Q2 2014 buy was QUESTCOR PHARMA INC: 200,000 shares worth $18.5M.
- Cormorant Asset Management added most to Omeros in Q2 2014, an estimated $7.86M increase.
- Cormorant Asset Management's biggest Q2 2014 reduction was PTC Therapeutics, cutting an estimated $8.56M.
- Cormorant Asset Management fully exited MEDIVATION, INC. in Q2 2014, selling an estimated $38.6M.
- Cormorant Asset Management's ten largest holdings make up 44% of its $377M portfolio in Q2 2014.
- Cormorant Asset Management opened 18 new positions and closed 10 in Q2 2014.
- Cormorant Asset Management's portfolio value fell 13% quarter-over-quarter to $377M.
Based on Cormorant Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.